FS.01: Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, November 16, 2024, 1:30 PM – 2:45 PM
FS.01 in Program Planner

• LIBerate-OLE - Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial (LIBerate-OLE)
• LIBerate-HeFH_OLE - Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE)
• PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
• YELLOW III - Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study

FS.02: Featured Science: Health Technology and the Future of Clinical Trials

Saturday, November 16, 2024, 1:30 PM – 2:45 PM
FS.02 in Program Planner

• DELIVER - Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER)
• MAPS-LLM - Manual versus AI-Assisted Clinical Trial Screening using Large-Language Models (MAPS-LLM)
• MyoMobile - Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care – A Randomized Parallel Group Trial (MyoMobile Study)
• mTECH-Rehab - Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECH-Rehab Randomized Controlled Trial (mTECH-Rehab)

FS.03: Featured Science: Getting Closer to the Summit: New HFpEF Treatments

Sunday, November 17, 2024, 8:00 AM – 9:15 AM
FS.03 in Program Planner

• Effect of finerenone on a hierarchical composite endpoint analyzed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF
• Efficacy and safety of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified sex-specific analysis of the FINEARTS-HF trial
• Finerenone and Risk of Hyperkalemia in Patients with Heart failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF)
• Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial

FS.04: Featured Science: Vascular Outcomes in the Spotlight

Monday, November 18, 2024, 8:00 AM – 9:15 AM
FS.04 in Program Planner

• Geographical variations of treatment disparities between Black and White patients with peripheral artery disease across the United States
• Legend 1 - Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (Legend 1 Trial)
• Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New insights from the CLEAR OUTCOMES Trial
• ONCO PE - Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial

FS.05: Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, November 18, 2024, 9:45 AM – 11:00 AM
FS.05 in Program Planner

• Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy (Accepted, not confirmed at time of publication)
• VALOR-HCM - Mavacamten Treatment in Patients with Obstructive HCM Referred for Septal Reduction Therapy: 128-Week Results from VALOR-HCM Trial
• Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study
• Impact of vutrisiran on markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial
• SCAN-MP - The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study (SCAN-MP)
• ATTR-Specific Medication in Dual Pathology Aortic Stenosis and Transthyretin Cardiac Amyloidosis.

FS.06: Featured Science: Novel Insights in Cardiovascular Interventional Outcomes

Monday, November 18, 2024, 1:30 PM – 2:45 PM
FS.06 in Program Planner

• Semaglutide Improves Cardiovascular Outcomes in Patients with a History of Coronary Artery Bypass Surgery and Overweight or Obesity: The SELECT Trial
• Five-Year Results from the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE)
• The impact of carbon monoxide to determine the in-hospital prognosis after acute coronary syndrome (ADDICT-ICCU) 
• Quantitative Assessment of Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement

FS.07: Featured Science: Incretion Modulation is the Time Now for Standard of Care

Monday, November 18, 2024, 1:30 PM – 2:45 PM
FS.07 in Program Planner

• Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy
• Effects of Tirzepatide on the Clinical and Symptom Burden of Patients with Heart Failure and a Preserved Ejection Fraction, Results from the SUMMIT Trial
• Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial

Abstracts and presentations are embargoed for release until the date and time of presentation at Scientific Sessions 2024. Information may not be released before then. Failure to honor embargo policies will result in the trial being withdrawn on site and barred from presentation. Any breach of the embargo policy may adversely affect participation in future AHA Sessions. Clinical trial sponsors must comply with the embargo guidelines established by the American Heart Association.

We understand that the sponsoring organization may be required to release top-line results in order to follow SEC (Security Exchange Commission) regulations, however, AHA must be notified before ANY release of information. Any level of information released without approval will be considered an embargo break. Please contact Mary Lu Hare if you are preparing a press release or for any questions.